Introduction
============

Somatic cell-cycle progression involves a doubling and then equal distribution of cellular components and macromolecules into the two daughter cells. As such, interphase (G~1~, S, and G~2~ phases) represents a long period of cellular growth (accumulation of mass due to anabolic processes), whereas mitosis is the period of division, which is short and accompanied by metabolic suppression ([@B1]). Consequently, a fundamental problem in mammalian cells is coordination of the metabolic status with cell-cycle progression ([@B2][@B3][@B6]). The progression through the G~1~ phase in the mammalian cell cycle is regulated by growth factor/mitogen--mediated signals and metabolic status. The latter remotely resembles a mechanism in yeast known as START and represents a nutrient-sensing metabolic checkpoint ([@B7][@B8][@B11]). The signaling network behind the G~1~-phase metabolic checkpoint coordinates the cell-cycle machinery and metabolic activities, thus ensuring the availability of energy and nucleotide precursors for genome replication and a timely transition from G~1~ to S phase ([@B12][@B13][@B15]). Also, it has been suggested that a sufficient storage of energy and biosynthetic materials may enable the execution of mitosis in a robust and all-or-none fashion ([@B16][@B17][@B19]). It is conceivable that a cell size--sensing mechanism may play a role in coordinating metabolic status (growth) and the G~2~/M-phase transition. This mechanism would allow cells to keep biosynthetic activity in check, ensuring sufficient biomass accumulation to produce daughter cells with the proper size ([@B20][@B21][@B24]). These studies implicate the existence of metabolic checkpoints during the G~1~/S- and G~2~/M-phase transition.

The AMP-activated protein kinase (AMPK)[^2^](#FN1){ref-type="fn"} complex is a central signaling node that keeps the cellular metabolic status in check by sensing changes in cellular AMP and other cellular metabolites, indicative of energy and nutrient status. Upon its activation, AMPK acts to maintain ATP homeostasis by rewiring metabolic programs to produce more energy and meanwhile suppressing many energy-consuming cellular processes, including cell-cycle progression ([@B25], [@B26]). It has been known that AMPK activation inhibits cell proliferation by increasing p21 and p27, two inhibitors of cyclin-dependent kinase (CDK) complex. Under conditions of insufficient nutrients, such as low glucose in cell culture medium, AMPK phosphorylates transcription factor p53, and this phosphorylation event mediates the suppression of G~1~-phase progression under glucose restriction ([@B27][@B28][@B30]). The mammalian target of rapamycin (mTOR), an evolutionarily conserved protein kinase, integrates environmental cues to coordinately regulate many fundamental cellular processes, including cell-cycle progression through the G~1~ phase. AMPK has been reported to directly phosphorylate key components of mTORC1 and consequently suppress mTORC1 signaling and the G~1~/S-phase transition ([@B31][@B32][@B36]). These findings clearly implicate AMPK as a key player in coupling the cellular metabolic status to the regulation of the G~1~/S-phase transition. However, the robustness of AMPK-dependent regulation on a myriad of fundamental cellular processes in response to metabolic stress suggests the presence of additional regulatory steps coupling AMPK and cell-cycle progression, and the molecular mechanisms behind these unrevealed regulatory steps remain to be explored.

The G~2~/M-phase transition is driven by a series of tightly regulated and coordinated signaling events that eventually lead to the activation of CDC2-cyclin B ([@B37][@B38][@B40]). Among these events, the rate-limiting step in directing mitosis entry is the activation of dual-specificity protein phosphatase CDC25C. The activation of CDC25C generally involves two steps, initiation and amplification ([@B41], [@B42]). The latter requires an array of protein kinases that can extensively phosphorylate CDC25C and change its conformation ([@B43][@B44][@B50]). Likewise, the initiation step of CDC25C activation requires multiple coordinated events, including dephosphorylation of serine 216, a conserved inhibitory phosphorylation, dissociation from the inhibitor 14-3-3, and change in the subcellular location ([@B51][@B52][@B55]). The amplification step of CDC25C activation is part of a positive-feedback loop that enables a rapid, robust, and irreversible mitosis entry, whereas the initiation step represents a surveillance mechanism that ensures the order and integrity of the cell-cycle machinery ([@B56]). Supporting this idea, the DNA damage--induced G~2~-phase checkpoint is largely mediated through inhibition of CDC25C, thus suppressing CDC2-cyclin B. Importantly, this is a p53-independent mechanism that is critical for the DNA damage response in most cancer cells because p53 loss of function is common in cancer cells ([@B57][@B58][@B60]). Because metabolic stress also causes cell-cycle arrest, it is conceivable that CDC25C may also represent a critical target of the metabolic checkpoint on cell-cycle progression.

In this study, we report a crucial role of AMPK in regulating the G~2~/M-phase transition. Unlike AMPK-dependent regulation on the G~1~/S transition, AMPK activation delays mitosis entry independently from its regulation on p21, p27, and mTORC1. Instead, AMPK directly phosphorylates CDC25C on serine 216, an inhibitory phosphorylation event that has been previously shown to retain CDC25C in the cytosol and keep it inactive ([@B51], [@B53], [@B54], [@B61], [@B62]). Either acute overexpression of CDC25C-S216A mutant or inhibition of WEE1 can reverse cell-cycle G~2~-phase arrest imposed by AMPK activation. Moreover, pharmacologic abrogation of AMPK-mediated cell-cycle arrest by WEE1 inhibitor induces cell death. These findings reveal a novel AMPK-dependent metabolic checkpoint on cell-cycle G~2~/M transition, and pharmacological abrogation of this checkpoint may represent a new therapeutic approach to treat cancers.

Results and discussion
======================

Activation of AMPK at G~2~ phase delays mitosis entry
-----------------------------------------------------

Previous studies have demonstrated an AMPK-dependent cell-cycle checkpoint at the G~1~/S-phase boundary, which may ensure the coordination of DNA synthesis in S phase with the availability of nutrients for nucleotide biosynthesis in G~1~ phase ([@B27], [@B33]). However, it is still unclear whether the G~2~/M-phase transition is regulated by AMPK and represents a checkpoint for the coordination of cell metabolism and cell-cycle progression. For this, we treated HeLa cells overnight with two mechanistically distinct pharmacologic activators of AMPK, 5-aminoimidazole-4-carboxamide 1-β-[d]{.smallcaps}-ribofuranoside (AICAR) or A 769662 (A7) ([@B63]). AICAR is considered as an AMP-mimetic compound that directly binds to a nucleotide-binding pocket in the AMPKα subunit and promotes AMPK kinase activities; A7 binds to a cleft between the AMPKα and β subunits and causes allosteric activation of the AMPK kinase complex ([@B63][@B64][@B66]). We found that both AICAR and A7 increased the percentage of cells in the G~1~ and G~2~ phases, as indicated by PI staining in combination with BrdU incorporation ([Fig. 1](#F1){ref-type="fig"}*A*). By contrast, the percentage of cells in mitosis indicated by phosphorylation of histone H3 (*pH3*) is reduced following AICAR and A7 treatment ([Fig. 1](#F1){ref-type="fig"}*A*). Notably, the disappearance of BrdU incorporation in AICAR group is probably due to the substrate competition between BrdU and AICAR, both of which are nucleotide analogs. Next, we repeated the experiment in the presence of nocodazole, a reversible inhibitor of microtubule polymerization, which blocks mitosis exit and therefore highlights the changes of mitotic entry following treatments. Both AICAR and A7 reduced the percentage of cells in mitosis compared with the control group ([Fig. 1](#F1){ref-type="fig"}*B*).

![**Pharmacologic activation of AMPK increases the percentage of cells in G~1~ and G~2~ phase.** *A*, HeLa cells were treated with 300 μ[m]{.smallcaps} A7 or 2 m[m]{.smallcaps} AICAR for 14 h before harvesting the samples. The percentage of cells in G~1~, S and G~2~ phase is indicated by PI staining in combination with BrdU incorporation (*top*). The percentage of cells in mitosis (*M*) is indicated by phosphorylation of histone H3 (*pH3*, *bottom*). The *scatter plot* indicates the percentage of M-phase cells treated with AMPK activator, and the percentage of M-phase cells in vehicle-treated cells was set to 100. *Error bars*, S.D. of triplicate samples. *B*, HeLa cells were treated with 300 μ[m]{.smallcaps} A7 or 2 m[m]{.smallcaps} AICAR in combination with 100 ng/ml nocodazole for 14 h. The percentage of cells in G~1~, S, and G~2~ phase is indicated by PI staining and BrdU incorporation (*top*). The percentage of M-phase cells is indicated by phosphorylation of histone H3 (*pH3*, *bottom*). The *scatter plot* indicates the percentage of M-phase cells treated with AMPK activator, and the percentage of M-phase cells in vehicle-treated cells was set to 100. *Error bars*, S.D. of triplicate samples. \*, *p* \< 0.05; \*\*, *p* \< 0.01.](zbc0161884910001){#F1}

We next applied radiochemical-based approaches to determine the activity of major catabolic pathways that could fuel the biosynthetic programs in cells released into G~1~ phase or G~2~ phase. We also included cells starved by serum removal as a control to indicate the baseline metabolic activity. Compared with cells at G~1~ phase or serum-starved cells, cells at G~2~ phase significantly up-regulated glycolysis, indicated by the detritiation of \[5-^3^H\]glucose; glucose consumption via the pentose phosphate pathway (PPP), indicated by ^14^CO~2~ release from \[1-^14^C\]glucose; and glutamine consumption through oxidative catabolism (glutaminolysis), indicated by ^14^CO~2~ release from \[U-^14^C\]glutamine ([Fig. 2](#F2){ref-type="fig"}*A*). In contrast, both mitochondria-dependent pyruvate oxidation through the tricarboxylic acid (TCA) cycle, indicated by ^14^CO~2~ release from \[2-^14^C\]pyruvate, and fatty acid β-oxidation, indicated by the detritiation of \[9,10-^3^H\]palmitic acid, were comparable among all three groups ([Fig. 2](#F2){ref-type="fig"}*B*). These data suggest that cells at G~2~ phase actively engage glucose and glutamine catabolic programs to meet their bioenergetic and biosynthetic demands.

![**Cells display heightened glucose and glutamine catabolism in G~2~ phase.** *A*, HeLa cells were released into G~1~ phase after mitotic shake-off or were release into G~2~ phase after double-thymidine arrest. Unsynchronized HeLa cells incubated in medium without serum for 6 h before the assay were used as control for the baseline metabolic activity. The indicated metabolic activities were determined by measuring the generation of ^3^H~2~O from \[5-^3^H\]glucose (glycolysis; *left*) or the generation of ^14^CO~2~ from \[1-^14^C\]glucose (PPP; *middle*) or from \[U-^14^C\]glutamine (glutaminolysis; *right*). Metabolic rate was normalized to serum-starved cells. *Error bars*, S.D. of triplicate samples. *B*, indicated metabolic activities were determined by measuring the generation of ^14^CO~2~ from \[2-^14^C\]pyruvate (TCA; *left*) and measuring the generation of ^3^H~2~O from \[9,10-^3^H\]palmitic acid (fatty acid β-oxidation; *right*). Metabolic rates were normalized to control. *Error bars*, S.D. of triplicate samples. \*\*, *p* \< 0.01.](zbc0161884910002){#F2}

Next, we sought to determine whether the acute activation of AMPK at G~2~ phase would cause a delay of mitosis entry. This would determine whether the delay of mitosis entry is a secondary effect from the G~1~/S-phase transition in the presence of AMPK activators. For this, we first synchronized cells at the G~1~/S boundary by double thymidine blockage and then released the cells into S phase and treated them with AMPK activators and nocodazole once they reached G~2~ phase ([Fig. 3](#F3){ref-type="fig"}*A*). In addition to AICAR and A7, we also included metformin and phenformin, two respiration chain complex I inhibitors, to indirectly activate AMPK by suppressing ATP production ([@B67]). Our results clearly showed that these AMPK activators reduced the percentage of cells in mitosis in a dose-dependent manner ([Fig. 3](#F3){ref-type="fig"}, *B* and *C*). Moreover, none of the acute treatment with these compounds caused significant apoptosis, as measured by PI uptake and cell-surface annexin V staining ([Fig. S1](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Collectively, our results suggest that activation of AMPK in cells at G~2~ phase delays mitosis entry.

![**Acute activation of AMPK at G~2~ phase delays mitosis entry.** *A*, *schematic view* of cell synchronization and the indicated treatments. Representative flow cytometric *dot plots* (*B*) and the scatter plot (*C*) indicate the percentage of M-phase cells treated with indicated compounds at G~2~ phase (A7+, 150 μ[m]{.smallcaps}; A7++, 300 μ[m]{.smallcaps}; AICAR+, 2 m[m]{.smallcaps}; AICAR++, 4 m[m]{.smallcaps}; metformin+, 2 m[m]{.smallcaps}; metformin++, 4 m[m]{.smallcaps}; phenformin+, 20 μ[m]{.smallcaps}; phenformin++, 100 μ[m]{.smallcaps}). The percentage of M-phase cells in vehicle-treated cells was set to 100. *Error bars*, S.D. of triplicate samples. \*\*, *p* \< 0.01.](zbc0161884910003){#F3}

DNA damage pathway and mTOR pathway are not involved in mediating AMPK-dependent regulation on G~2~/M-phase transition
----------------------------------------------------------------------------------------------------------------------

It has been well-established that cells in G~2~ phase with damaged DNA are prevented from entering into mitosis, and the control mechanisms behind this are known as the G~2~ checkpoint ([@B60], [@B68][@B69][@B71]). To determine whether activation of AMPK cross-talks with the DNA damage pathway and causes G~2~ arrest, we treated cells with AICAR at G~2~ phase and examined molecules involved in the DNA damage response pathways in cells collected at various time points. Doxorubicin, a reagent that causes DNA adducts and activates the DNA damage response, readily induced phosphorylation of checkpoint kinase 1 (Chk1) and histone H2AX (H2AX), two characteristic biomarkers of the DNA damage response ([@B72]). However, treatment with AICAR failed to induced any visible phosphorylation of Chk1 and H2AX ([Fig. 4](#F4){ref-type="fig"}*A*). Previous studies have demonstrated that AMPK phosphorylates p53 and causes the accumulation of p21, a transcriptional target of p53 that mediates p53-dependent regulation on cell cycle ([@B28], [@B73][@B74][@B75]). In a different cellular context, AMPK was reported to regulate p27 and induce autophagy ([@B29]). Both p21 and p27 are CDK inhibitors and play critical roles in cell-cycle regulation ([@B76], [@B77]). However, we have found that the treatment with AICAR failed to induce the expression of p21 or p27 ([Fig. S2](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Our findings are also consistent with earlier reports showing no detectable p53 protein in HeLa cells ([@B78], [@B79]).

![**Pharmacological activation of AMPK on cells in G~2~ phase does not activate the DNA damage pathway or suppress the mTOR pathway.** *A*, HeLa cells were treated with or without 2 m[m]{.smallcaps} AICAR at G~2~ phase alone with nocodazole. Cells were collected at different time points (T0, 7 h after the second thymidine release when AMPK activators and nocodazole were added; T1, 2 h after T0; T2, 4 h after T0; T3, 6 h after T0). The level of the indicated proteins in HeLa cells was determined by immunoblotting. Doxorubicin (1 μg/ml), as a DNA damage-inducing agent, was included as a positive control. *B*, HeLa cells were treated with 300 μ[m]{.smallcaps} A7, 2 m[m]{.smallcaps} AICAR, 200 n[m]{.smallcaps} rapamycin, or 2 μ[m]{.smallcaps} torin at G~2~ phase alone with nocodazole. Cells were collected 12 h after the second thymidine release. The level of the indicated proteins in HeLa cells was determined by immunoblot. *C*, the percentage of M-phase cells with the indicated treatments was determined by pH3 staining. The representative flow cytometric dot plots (*left*) and scatter plot (*right*) indicate the percentage of M-phase cells in different groups. The percentage of M-phase cells in vehicle-treated cells was set to 100. *Error bars*, S.D. of triplicate samples.](zbc0161884910004){#F4}

It has also been reported that AMPK regulates cell-cycle progression through directly inhibiting mTORC1 complex, which is the central player in sensing nutrients and coordinately regulating cell-cycle progression ([@B31], [@B33][@B34][@B36]). To determine whether mTORC1 is involved in mediating AMPK-dependent regulation on G~2~/M transition, we treated cells with either AMPK activators or mTORC1 inhibitors at G~2~ phase and examined the phosphorylation of mTORC1 effector molecules, P70 kinase and ribosomal protein S6, in cells collected at the time when control cells start entering into mitosis. Whereas A7 treatment and the mTORC1 inhibitor treatments led to the suppression of mTORC1, as indicated by the loss of phosphorylation of P70 kinase and S6, AICAR treatment failed to suppress mTORC1 activities ([Fig. 4](#F4){ref-type="fig"}*B*). Importantly, neither rapamycin nor torin treatment delayed mitosis entry ([Fig. 4](#F4){ref-type="fig"}*C*). Collectively, these findings suggested that mTORC1 is not involved in mediating AMPK-dependent regulation of the G~2~/M transition.

AMPK phosphorylates CDC25C at serine 216 in vitro and in cells
--------------------------------------------------------------

The activity of CDKs oscillates throughout the cell cycle and determines the transition between different cell-cycle phases ([@B76], [@B77]). Mitosis entry is driven by CDC2-cyclin B, which is coordinately regulated by CDC25, WEE1, and MYT1. WEE1 and MYT1 phosphorylate and keep CDC2-cyclin B inactive in G~2~ phase. CDC25 activates CDC2-cyclin B and drives cells into mitosis by dephosphorylating the inhibitory phosphorylation sites on CDC2-cyclin B ([Fig. 5](#F5){ref-type="fig"}*A*). Given that the mitotic regulators mentioned above are all regulated by phosphorylation and AMPK is a signaling protein kinase, we asked whether AMPK is capable of directly phosphorylating and modulating any of the above mitotic regulators. Previous studies have revealed the optimal consensus phosphorylation motif for AMPK ([@B33], [@B80]). We therefore applied a bioinformatics tool (Scansite3 ([@B81])) to search for putative AMPK-mediated phosphorylation motifs in CDC25C, WEE1, MYT1, CDC2, and cyclin B1. The inspection of these protein sequences revealed one putative AMPK phosphorylation site, serine 216, in CDC25C ([Fig. 5](#F5){ref-type="fig"}*B*). The phosphorylation of serine 216 plays a key role in the temporal and spatial regulation of CDC25C and the G~2~/M transition in response to DNA damage and during normal cell-cycle progression ([@B51], [@B53], [@B54], [@B61], [@B62]). To validate serine 216 as an AMPK phosphorylation site in CDC25C, we took an integrated stepwise approach. We first transfected cells with constructs expressing either WT or mutant CDC25C (serine to alanine/S216A) fused to the Myc epitope tag (Myc-CDC25C), immunoprecipitated CDC25C with anti-Myc epitope tag antibodies, and then immunoblotted the protein samples using a phosphorylation-specific antibody that recognizes the phosphorylated AMPK consensus motif ([@B33], [@B80]). Whereas the phospho-AMPK substrate motif antibody recognized WT CDC25C, the S216A mutation abolished such recognition, suggesting that Ser-216 is within the AMPK substrate motif in CDC25C ([Fig. S3*A*](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Second, we generated recombinant CDC25C fused to glutathione *S*-transferase (GST-CDC25C) and a non-related GST-tagged protein and phosphorylated these proteins with recombinant AMPK or extracellular signal-regulated kinase 1 (ERK1) or PBS control. ERK readily phosphorylated CDC25C at threonine 48, as we reported previously ([@B49]). However, only the AMPK-mediated phosphorylation site in CDC25C was recognized by the phospho-AMPK substrate motif antibody or the pSer-216 antibody ([Fig. 5](#F5){ref-type="fig"}*C*). Third, we treated cells with AICAR or transfected cells with either a control construct or a construct expressing a constitutively active mutant of the AMPK catalytic subunit (AMPK-CA) ([@B82]) and then immunoblotted with the pSer-216 antibody. Both pharmacologic and genetic activation of AMPK readily enhanced the phosphorylation of Ser-216 in CDC25C ([Fig. 5](#F5){ref-type="fig"}*D* and [Fig. S3*B*](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Finally, we applied a chemical genetic approach to validate Ser-216 in CDC25C as a genuine AMPK-mediated phosphorylation site in cells ([@B83][@B84][@B85]). This approach is based on the concept that protein kinase can only use ATP as a phosphate donor; however, the point mutation of a conserved gatekeeper residue in the ATP-binding pocket of a protein kinase would allow mutant protein kinase (analog-specific (AS)) to utilize ATP analog (ATPγS) as a phosphate donor. The specific labeling of kinase substrate with thiophosphate (thioP), followed by protein immunoprecipitation and alkylation, would enable the recognition of AS mutant--dependent phosphorylation with a thioP-specific antibody. This approach has been applied to identify direct substrates of various protein kinases, including AMPK ([@B83], [@B86]). Thus, we co-transfected cells with a construct expressing Myc-tagged CDC25C as well as a construct expressing either FLAG-tagged WT or AS-AMPK and showed that Myc-tagged CDC25C could be labeled with thioP only in the presence of AS-AMPK ([Fig. 5](#F5){ref-type="fig"}*E*). Then we followed up the above experiment by co-transfecting cells with a construct expressing AS-AMPK as well as a construct expressing either Myc-tagged WT or S216A CDC25C. The recognition by thioP-specific antibody was significantly compromised by S216A mutation ([Fig. 5](#F5){ref-type="fig"}*F*), suggesting that Ser-216 is a direct phosphorylation site and very likely the only phosphorylation site of AMPK on CDC25C.

![**AMPK phosphorylates CDC25C at serine 216 *in vitro* and in cells.** *A*, model showing that G~2~/M-phase transition is regulated by CDC25C and WEE1. *B*, potential AMPK phosphorylation motif of CDC25C was predicted by Scansite3. The AMPK consensus phosphorylation motif and the predicted motif are shown in *single-letter amino acid code*. Positions marked as *red* showed the similarity between the two motifs, and the predicted phosphorylation site of CDC25C is marked as *blue. C*, bacterially expressed GST-CDC25C or GST was incubated with recombinant AMPK or ERK in an *in vitro* phosphorylation assay. Proteins were resolved by SDS-PAGE and immunoblotting for the indicated antibodies. *D*, HeLa cells were transfected with a construct expressing a constitutively active mutant of the AMPK catalytic subunit (AMPK-CA) or a blank control plasmid for 2 days, and the expression of the indicated proteins in transfected cells was determined by immunoblot. *E*, analog-sensitive kinase assay in cells. HeLa cells were transfected with Myc-CDC25C together with either WT-AMPKα2 or AS-AMPKα2 and treated with ATPγS analog as a phosphodonor. CDC25C was immunoprecipitated (*IP*) with Myc tag antibody and blotted (*WB*) with the indicated antibodies. *F*, analog-sensitive kinase assay in cells. HeLa cells were transfected with AS-AMPKα2 together with either WT or S216A mutant Myc-CDC25C and treated with ATPγS analog as a phosphodonor. CDC25C was immunoprecipitated with Myc tag antibody and blotted with the indicated antibodies.](zbc0161884910005){#F5}

Acute modulation of CDC25C or WEE1 partially relieves AMPK-dependent inhibition of the G~2~/M-phase transition
--------------------------------------------------------------------------------------------------------------

Our data on AMPK-dependent phosphorylation of Ser-216 on CDC25C suggested that AMPK suppresses the G~2~/M-phase transition through the phosphorylation and inhibition of CDC25C. CDC25C activates CDC2-cyclin B and promotes the G~2~/M-phase transition by antagonizing WEE1 (*i.e.* by dephosphorylating WEE1-dependent phosphorylation sites on CDC2-cyclin B) ([@B42], [@B87], [@B88]). We therefore reasoned that the abrogation of WEE1 or the abrogation of Ser-216 on CDC25C would relieve AMPK-dependent inhibition of the G~2~/M-phase transition ([Fig. 6](#F6){ref-type="fig"}*A*). To test this, we first took a pharmacological approach, using MK1775, to block WEE1 activity in the presence of AMPK activators. MK1775 is a potent WEE1 inhibitor and allows us to acutely block WEE1 activity in cells synchronized at G~2~ phase without interfering with the cell-cycle synchronization process ([@B89]). Because a pharmacological inhibitor readily suppresses its target upon addition, we treated cells with MK1775 at the same time as we added AMPK inhibitors, ensuring a minimal perturbation by the compound on G~2~-phase progression ([Fig. 6](#F6){ref-type="fig"}*B*). Supporting the idea that the inhibition of WEE1 may antagonize AMPK-mediated suppression on CDC25C, neither A7 nor AICAR treatment delayed mitosis entry in the presence of MK1775; however, A7 and AICAR treatment consistently reduced the percentage of cells in mitosis in the absence of MK1775 ([Fig. S4, *A* and *B*](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Next, we applied a genetic approach to knock down WEE1 by transfecting a WEE1-specific siRNA. To avoid perturbing the normal cell-cycle progression following a long-term WEE1 knockdown, we transfected cells with WEE1 siRNA when synchronized cells were released into S phase and collected samples 12 h later to examine the protein level of WEE1 and cell-cycle status ([Fig. 6](#F6){ref-type="fig"}*B*). The protein level of mammalian WEE1 oscillates during the cell cycle and thus indicates a short half-life of WEE1 protein. This allows us to deplete WEE1 in a short time frame by siRNA ([Fig. 6](#F6){ref-type="fig"}*C*) ([@B90][@B91][@B92]). Consistent with our data on MK1775, siRNA-mediated acute knockdown of WEE1 also partially relieved AMPK-mediated suppression of the G~2~/M transition ([Fig. 6](#F6){ref-type="fig"}*C* and [Fig. S4*C*](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Last, we sought to genetically modulate the phosphorylation of Ser-216 on CDC25C and examine its effect on G~2~/M-phase transition in the context of AMPK activation. To minimize the perturbation of constitutive overexpression of CDC25C on normal cell-cycle progression, we established a cell line stably expressing a doxycycline-inducible CDC25C (S216A) mutant, which enables the acute induction of CDC25C (S216A) following doxycycline treatment when synchronized cells were released into S phase ([Fig. 6](#F6){ref-type="fig"}*B*). We confirmed the acute induction of CDC25C (S216A) by immunoblotting and showed that such treatment partially relieved AMPK-mediated suppression of the G~2~/M-phase transition ([Fig. 6](#F6){ref-type="fig"}*D* and [Fig. S4*D*](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Of note, neither the WEE1 siRNA nor the induction of CDC25C (S216A) in the context of AMPK activation caused additional stresses and induced cell death during the time frame of experiments ([Fig. S5](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Taken together, our results suggest that AMPK-mediated phosphorylation of Ser-216 on CDC25C represents a mechanism of cell-cycle checkpoint.

![**Acute induction of CDC25C or suppression of WEE1 partially reverses the effect of AMPK activation on the G~2~/M-phase transition.** *A*, model showing that the G~2~/M-phase transition is regulated by CDC25C and WEE1. *B*, *schematic view* of cell synchronization and the indicated treatments. Synchronized HeLa cells that stably express reverse tetracycline-controlled transactivator and doxycycline-inducible CDC25C were treated with doxycycline when cells were released from the second thymidine block (G~1~/S boundary). Synchronized HeLa cells were transfected with WEE1 siRNA at the G~1~/S boundary or treated with WEE1 inhibitor at G~2~ phase (7 h after cells were released from the second thymidine block), respectively. AMPK activators and nocodazole were added when cells are in G~2~ phase. *C*, the percentage of M-phase cells in HeLa cells transfected with scramble siRNA or WEE1 siRNA was determined by phosphorylation of histone H3 (*pH3*) staining. The percentage of M-phase cells in vehicle-treated cells was set to 100, and the value of AMPK activator--treated cells was normalized to that of vehicle-treated cells. *Error bars*, S.D. of triplicate samples (*left*). Cell lysates were blotted with the indicated antibodies (*right*). *D*, the percentage of M-phase cells in HeLa cells that stably express reverse tetracycline transcriptional activator (*Ctrl*) or CDC25C-S216A following doxycycline treatment was determined by phosphorylation of histone H3 (*pH3*) staining. The percentage of M-phase cells in vehicle-treated cells were set to 100, and the value of AMPK activator--treated cells was normalized to that of vehicle-treated cells. *Error bars*, S.D. of triplicate samples (*left*). Cell lysates were blotted with the indicated antibodies (*right*). \*, *p* \< 0.05; \*\*, *p* \< 0.01.](zbc0161884910006){#F6}

WEE1 inhibitor synergizes with AMPK activators to induce cell death
-------------------------------------------------------------------

AMPK is a central sensor of cellular energy status and therefore plays a key role in maintaining metabolic and bioenergetic homeostasis ([@B26], [@B93]). We envisioned that AMPK-mediated suppression on G~2~/M-phase transition may represent a metabolic checkpoint that ensures the coordination of sequential cell-cycle transitions with metabolic status. As such, abrogation of the checkpoint may reduce the ability of cells to survive. To test this idea, we treated cells with AMPK activator, WEE1 inhibitor, or a combination of these two and monitored the cell growth curve. Whereas single-agent treatment demonstrated a moderate ability to suppress cell growth, either A7 or AICAR in combination with MK1175 led to a synergistic effect on suppressing cell growth ([Fig. 7](#F7){ref-type="fig"}*A*). Moreover, the growth suppression correlated with cell death induction, as measured by cell surface staining of annexin V and cellular uptake of PI, following the treatment with these reagents ([Fig. 7](#F7){ref-type="fig"}*B*). Our studies suggest that abrogation of AMPK-dependent G~2~ checkpoint response induces cell death and may represent an attractive cancer therapeutic strategy.

![**Pharmacological ablation of G~2~ checkpoint synergizes with AMPK activators to induce cell death.** *A*, HeLa cells were treated with AMPK activators, MK1775, or a combination of the two, and the growth curve was determined by live cell imagine analysis (IncuCyte ZOOM^TM^). *Error bars*, S.D. of quadruplicate samples. *B*, HeLa cells were treated with AMPK activators, MK1775, or a combination for 48 h, and cell death was determined by staining with FITC-conjugated annexin V and PI followed by FACS analysis. The percentage of apoptotic and dead cells was determined from three experiments. *Bars*, mean ± S.D. \*\*, *p* \< 0.01.](zbc0161884910007){#F7}

Metabolic stress suppresses the G~2~/M transition partially through AMPK
------------------------------------------------------------------------

We next sought to assess the impact of metabolic stress on AMPK and cell-cycle G~2~/M transition. We first applied glucose-free conditional medium and hexokinase inhibitor, 2-deoxyglucose (2DG), to induce an acute metabolic stress and assess the activation of AMPK. Given that the average duration of G~2~ phase is between 2 and 5 h, we reasoned that the acute condition (1 h) is more relevant to assess the impact of metabolic stress on cell-cycle G~2~/M transition. Under this condition, we found that U2OS cells but not HeLa cells respond to acute metabolic stress by enhancing AMPK activity, as indicated by the increase of AMPK autophosphorylation and phosphorylation of ACC ([Fig. 8](#F8){ref-type="fig"}*A*). Previous studies have shown that HeLa cells are deficient in liver kinase B1 (LKB1), an AMPK-activating kinase ([@B94]), and we have also confirmed LKB1 deficiency in HeLa cells by Western blotting ([Fig. 8](#F8){ref-type="fig"}*B*). LKB1 deficiency probably renders HeLa cells resistant to metabolic stress-induced activation of AMPK because AMP/ADP promotes the conformational change of AMPK that will facilitate the phosphorylation by LKB1 and consequentially enhance AMPK activity ([@B95], [@B96]). As such, we chose U2OS cells to further assess the impact of metabolic stress on AMPK and on the G~2~/M transition. For this, we applied siRNA to transiently knock down AMPKα1 in U2OS cells ([Fig. 8](#F8){ref-type="fig"}*C*). Both the procedure of transient transfection and the time frame (48 h) required to achieve an efficient knockdown of AMPKα1 interfered with the standard protocol for double thymidine synchronization. We therefore chose to treat cells with the indicated siRNA for 48 h and then applied nocodazole, to hold cells in mitosis, with or without metabolic stress. As [Fig. 8](#F8){ref-type="fig"}*D* shows, metabolic stress imposed by either glucose starvation or glycolysis inhibitor 2DG significantly suppressed the percentage of cells entering into mitosis following nocodazole treatment. Importantly, AMPKα1 knockdown partially relieved metabolic stress-mediated suppression on the G~2~/M-phase transition ([Fig. 8](#F8){ref-type="fig"}*D*). Collectively, our results suggested that acute metabolic stress (nutrient starvation or metabolic inhibitor) activates AMPK and suppresses the G~2~/M-phase transition.

![**Metabolic stress suppresses G~2~/M transition partially through AMPK.** *A*, U2OS and HeLa cells were cultured in glucose-free medium or treated with 10 m[m]{.smallcaps} 2DG for 1 h. The level of the indicated proteins in cells was determined by immunoblotting. *B*, U2OS and HeLa cells were collected, and the level of the indicated proteins was determined by immunoblot. *C*, U2OS cells were transfected with scrambled siRNA or AMPKα1 siRNA for 48 h. The level of the indicated proteins in cells was determined by immunoblot. *D*, U2OS cells were transfected with scrambled siRNA or AMPKα1 siRNA for 48 h and then incubated in control or glucose-free medium (*GF*, *top*) or treated with a different concentration of 2DG (*bottom*) along with 100 ng/ml nocodazole for 14 h. The percentage of M-phase cells was determined by the phosphorylation of histone H3 (*pH3*) staining. The percentage of M-phase cells in control medium was set to 100, and the value of cells in GF medium or 2DG-treated cells was normalized to their control. *Error bars*, S.D. of triplicate samples.](zbc0161884910008){#F8}

Cell-cycle checkpoints are critical surveillance mechanisms that monitor the integrity and fidelity of genome replication and separation and thus ensure the order and timely execution of cell-cycle transitions ([@B97][@B98][@B99]). In addition, mammalian cells have evolved to rapidly respond to changes of internal metabolic status and external nutrient levels by engaging a mechanism of adaptation, which requires robust molecular machineries that sense metabolic signals. The consequences of such adaptation include not only metabolic rewiring but also commitments on cell-cycle progression, cell death, and many other basic or specialized cellular functions ([@B100][@B101][@B102]). Previous studies have shown that AMPK is crucial for the survival of cells by acting on an array of signaling and biochemical pathways to rapidly restore the energy status upon a variety of metabolic stresses ([@B25], [@B26]). Our studies implicate AMPK as a critical signaling node that interconnects with cell-cycle machinery through a direct phosphorylation and suppression of CDC25C. This allows cells to constantly inspect the metabolic status, halt the cell-cycle progression upon perturbations, and therefore ensure the cellular metabolic fitness and homeostasis of the progenies. Our studies further suggest that phosphorylation of Ser-216 in CDC25C is not only an evolutionarily conserved mechanism in normal cell-cycle regulation, but also a shared G~2~-phase checkpoint mechanism in mammalian cells in response to both DNA damage and metabolic stress ([@B51], [@B53], [@B54], [@B61], [@B62]). These findings together support the idea that some key elements of the cellular stress response pathways are shared among different stresses and are conserved across many species ([@B103], [@B104]). In multicellular eukaryotes, programmed cell death (apoptosis) occurs when the dose of stress exceeds tolerance limits or when adaptive pro-survival checkpoint mechanisms are eliminated ([@B105][@B106][@B107]). MK1775 has displayed anti-tumor activities in various preclinical models and has been evaluated in clinical trials as monotherapy and adjuvant therapy ([@B108], [@B109]). Our studies therefore suggest that abrogation of the metabolic checkpoint on G~2~/M-phase transition by WEE1 inhibitor may lead to premature mitosis entry and consequent cell death and therefore holds promise for therapeutically targeting cancer ([@B110][@B111][@B112]).

Experimental procedures
=======================

Cell culture and reagents
-------------------------

HeLa (human cervical cancer cells, ATCC) and U2OS (human osteosarcoma cells, ATCC) were grown at 37 ºC/5% CO~2~ in Dulbecco\'s modified Eagle\'s medium (DMEM; Corning Cellgro, Thermo Fisher Scientific, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco-Invitrogen, Carlsbad, CA) and 1% penicillin-streptomycin (Corning). Cell line identity was authenticated by short tandem repeat analysis. Glucose-free DMEM was supplemented with 10% (v/v) heat-inactivated dialyzed fetal bovine serum, which was made dialyzing against 100 volumes of distilled water (five changes in 3 days) using Slide-ALyzer^TM^ G~2~ dialysis cassettes with cut-through MW size 2K (Thermo Fisher Scientific) at 4 °C. AICAR, A769662, rapamycin, torin, metformin, phenformin, 2-deoxy-[d]{.smallcaps}-glucose, and nocodazole were purchased from Caymen Chemical (Ann Arbor, MI). MK1775 was purchased from MedKoo Biosciences (Morrisville, NC).

siRNA transfection
------------------

The siRNA oligonucleotides corresponding to human WEE1 and AMPKα1 were purchased from Fisher. siRNA oligonucleotides (20 n[m]{.smallcaps}) were transfected into cells using Lipofectamine RNAiMAX reagent (Invitrogen). After 12 h of transfection (transfection when cells were released from the second thymidine block) or after 48 h of transfection (transfection in non-synchronized cells), immunoblots were carried out to examine the knockdown of targeted proteins.

RNA isolation, reverse transcription, and quantitative PCR
----------------------------------------------------------

Total RNA was isolated using an RNA extraction kit (Zymo Research, Irvine, CA) and was reverse-transcribed using random hexamer and Moloney murine leukemia virus reverse transcriptase (Invitrogen). SYBR Green-based quantitative RT-PCR for specific genes was performed using the Applied Biosystems real-time PCR system. Samples for each experimental condition were run in triplicate and were normalized to β~2~-microglobulin to determine relative expression levels. Primer sequences ([Table S2](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)) were obtained from the Primer Bank ([@B113]).

Protein extraction and Western blot analysis
--------------------------------------------

Cells were harvested, lysed, and sonicated at 4 °C in a lysis buffer (50 m[m]{.smallcaps} Tris-HCl, pH 7.4, 150 m[m]{.smallcaps} NaCl, 0.5% SDS, 5 m[m]{.smallcaps} sodium pyrophosphate, protease, and phosphatase inhibitor tablet). Cell lysates were centrifuged at 13,000 × *g* for 15 min, and the supernatant was recovered. The protein concentrations were determined using the Pierce^TM^ BCA protein assay kit (Thermo Fisher Scientific). After 5 min boiling in 4× NuPAGE® LDS sample buffer with 10× reducing solution (Thermo Fisher Scientific), the proteins were separated by NuPAGE 4--12% protein gels (Thermo Fisher Scientific), transferred to polyvinylidene difluoride membranes by using the iBlot gel transfer device (Thermo Fisher Scientific), and probed with the appropriate primary antibodies ([Table S1](http://www.jbc.org/cgi/content/full/RA117.001379/DC1)). Membrane-bound primary antibodies were detected using secondary antibodies conjugated with horseradish peroxidase. Immunoblots were developed on films using the enhanced chemiluminescence technique. Density of each band was analyzed by ImageJ software, and all values were normalized with actin. All image data are representative of at least two independent experiments.

Synchronization and cell-cycle analysis
---------------------------------------

HeLa cells were synchronized to the G~1~/S border by double thymidine blockage and released into fresh medium for 7 h until they reached G~2~ phase. In some experiments, HeLa cells were synchronized in mitosis by a shake-off after 14 h of incubation in 100 ng/ml nocodazole, washed, and allowed to transition to G~1~ phase. U2OS cells were synchronized to M phase by 14 h of incubation in 100 ng/ml nocodazole.

BrdU incorporation was used to evaluate the amount of S-phase cells. In short, after labeling of cells with BrdU (Sigma-Aldrich), cells were fixed in ice-cold ethanol, treated with HCl to denature the DNA, and stained with PI and anti-BrdU antibody. Mitotic cells were examined by intracellular staining of phospho-histone H3 using a hypotonic buffer protocol described previously ([@B114]). Cell-cycle analysis was done with a flow cytometer (NovoCyte, ACEA Biosciences, San Diego, CA), and FlowJo version 10 was used to analyze the flow cytometry data.

In vitro phosphorylation
------------------------

The bacterial expression vectors for GST-tagged CDC25 fragments were generated by PCR amplification of the encoding human CDC25C cDNA, followed by subcloning of the cDNA into pGEX-4T3 vector. Activated recombinant ERK (p42 MAPK) was prepared by incubating MBP-MAPK with constitutively activated MBP-MKK1 ([@B115]). GST- and MBP-tagged recombinant proteins were expressed in bacteria and purified as described previously ([@B49], [@B115], [@B116]). AMP kinase was purchased from Millipore (Burlington, MA). The kinase reactions were performed in 10 μl of reaction mixture (1 μl of 10× kinase buffer and 0.25 m[m]{.smallcaps} ATP), AMPK (1 unit), and 1 μg of the indicated substrates for 30 min at 30 °C. The reaction mixtures were boiled in SDS sample buffer and subjected to SDS-PAGE analysis and a Western blot assay.

Metabolic activity analysis
---------------------------

The radioactive tracers are described in [Table S3](http://www.jbc.org/cgi/content/full/RA117.001379/DC1). The activity of various metabolic pathways was determined by the rate of detritiation or ^14^CO~2~ released from radioactive tracers, as described previously ([@B117], [@B118]). Specifically, glycolysis and fatty acid β-oxidation were determined by measuring the detritiation of \[5-^3^H\]glucose ([@B119], [@B120]) or by measuring the detritiation of \[9,10-^3^H\]palmitic acid ([@B121]), respectively. In brief, 1 million cells were suspended in 0.5 ml of fresh medium. The experiment was initiated by adding 1 μCi of radioactive tracer, and 2 h later, medium was transferred to a 1.5-ml microcentrifuge tube containing 50 μl of 5 [n]{.smallcaps} HCl. The microcentrifuge tubes were then placed in 20-ml scintillation vials containing 0.5 ml of water with the vials capped and sealed. ^3^H~2~O was separated from other radiolabeled metabolites by evaporation diffusion for 24 h at room temperature. A cell-free sample containing 1 μCi of radioactive tracer was included as a background control.

Glutaminolysis, TCA cycle (oxidation of pyruvate), and glucose oxidation flux through the PPP were determined by the rate of ^14^CO~2~ released from \[U-^14^C\]glutamine ([@B122]), the rate of ^14^CO~2~ released from \[2-^14^C\]pyruvate ([@B123]), and the rate of ^14^CO~2~ released from \[1-^14^C\]glucose with some modifications ([@B123]). Whereas the difference in the rate of ^14^CO~2~ released from \[1-^14^C\]glucose and \[6-^14^C\]glucose was used to determine the PPP activity, we consistently found that the ^14^CO~2~ production from \[6-^14^C\]glucose was close to the background in cells. PPP activity was therefore determined as the rate of ^14^CO~2~ released from \[1-^14^C\]glucose. In brief, 3 million cells were suspended in 0.5 ml of fresh medium. To facilitate the collection of ^14^CO~2~, cells were dispensed into 7-ml glass vials (TS-13028, Thermo Fisher Scientific) with a PCR tube containing 50 μl of 0.2 [m]{.smallcaps} KOH glued on the sidewall. After adding 0.5 μCi of radioactive tracer, the vials were capped using a screw cap with a rubber septum (TS-12713, Thermo Fisher Scientific). The assay was stopped 2 h later by injection of 100 μl of 5 [n]{.smallcaps} HCl, and the vials were kept at room temperature overnight to trap the ^14^CO~2~. The 50 μl of KOH in the PCR tube was then transferred to scintillation vials containing 10 ml of scintillation solution for counting. A cell-free sample containing 0.5 μCi of radioactive tracer was included as a background control.

Phosphorylation of CDC25C in cells
----------------------------------

HeLa cells were seeded at 4 × 10^5^ cells/35-mm dish and were transfected with 1.25 μg of WT- or AS-AMPKα2 and 1.25 μg of WT- or S216A-Myc-CDC25C using the Lipofectamine (Thermo Fisher Scientific). Forty-eight hours after transfection, cells were washed twice with serum-free DMEM and incubated for 2 h before stimulation with 300 μ[m]{.smallcaps} A769662 for 20 min. Following stimulation, 200 μl of phosphorylation buffer (20 m[m]{.smallcaps} HEPES (pH 7.3), 100 m[m]{.smallcaps} KOAc, 5 m[m]{.smallcaps} NaOAc, 2 m[m]{.smallcaps} MgOAc~2~, 1 m[m]{.smallcaps} EGTA, 10 m[m]{.smallcaps} MgCl~2~, 0.5 m[m]{.smallcaps} DTT, 5 m[m]{.smallcaps} creatine phosphate, 57 μg/ml creatine kinase, 30 μg/ml digitonin, 5 m[m]{.smallcaps} GTP (Abcam), 0.1 m[m]{.smallcaps} ATP, 0.1 m[m]{.smallcaps} *N*^6^-(phenethyl) ATPγS (Abcam), 0.45 m[m]{.smallcaps} AMP (Abcam), 1× phosphatase inhibitor mixture I and II (Sigma), and 1× complete protease inhibitors (Sigma)) was added. After a 20-min incubation at room temperature, 200 μl of 2× radioimmune precipitation assay buffer (100 m[m]{.smallcaps} Tris, pH 8, 300 m[m]{.smallcaps} NaCl, 2% Nonidet P-40, 0.2% SDS, and 20 m[m]{.smallcaps} EDTA) with 2.5 m[m]{.smallcaps} *p*-nitrobenzyl mesylate (Abcam) and 5% DMSO was added, and cells were incubated for an additional 1 h at room temperature. The cell lysates were then subjected to immunoprecipitation using agarose beads coupled to Myc tag antibody.

Constructs and generation of CDC25C-inducible stable cell lines
---------------------------------------------------------------

Plasmid pECE-AMPKα2 WT, M93G, and pEBG-AMPKα1 (1--312) were obtained from Addgene (Cambridge, MA) ([@B82], [@B86]). The pRetro-TRE3G vector (Clontech, Mountain View, CA) that expresses doxycycline-inducible CDC25C-S216A was generated by a recombination-based cloning method (In-Fusion Cloning Kits, Clontech) followed by site-directed mutagenesis (New England Biolabs, Ipswich, MA). Myc-tagged CDC25C-S216A expression plasmid was generated by subcloning pRetro-TRE3G-CDC25C-S216A into pCS2+MT plasmid.

The Amphopack 293 cells were transfected with the pRetro-TRE3G vector using Lipofectamine (Thermo Fisher Scientific) to produce retrovirus. HeLa cells that stably expressed reverse tetracycline-controlled transactivator (rtTA, Clontech) were infected with the retrovirus and treated with 2 μg/ml puromycin (Sigma) and maintained in puromycin-containing medium.

Cell growth and cell death
--------------------------

Cell proliferations were measured by the IncuCyte cell proliferation assay. Cells were harvested by trypsinization, counted on a Countess automated cell counter (Invitrogen), and plated at 4000 cells/well on 96-well tissue culture plates in four replicates. Photomicrographs were taken every 3 h using an IncuCyte live cell imager (Essen Biosciences, Ann Arbor, MI), and confluence of the cultures was measured using IncuCyte software (Essen Biosciences) over 48 h in culture. For the cell death assay, cells were stained with annexin V--APC and PI and evaluated for apoptosis by flow cytometry according to the manufacturer\'s protocol (BD PharMingen, San Diego, CA).

Statistical analysis
--------------------

*p* values were calculated with Student\'s *t* test. *p* values \< 0.05 were considered significant, with *p* values \< 0.05 and *p* values \< 0.01 indicated as with single and double asterisks, respectively.

Author contributions
====================

Y. S. data curation; Y. S. formal analysis; Y. S. validation; Y. S. and J. W. S. investigation; Y. S., J. W. S., and X. C. methodology; Y. S. and R. W. writing-original draft; Y. S., J. W. S., X. C., and R. W. writing-review and editing; R. W. conceptualization; R. W. supervision.

Supplementary Material
======================

###### Supporting Information

This work was supported by National Institute of Health Grant 1R01AI114581, V-Foundation Grant V2014-001, American Cancer Society Grant 128436-RSG-15-180-01-LIB, and a research grant from the CancerFree KIDs Foundation (to R .W). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article contains [Tables S1--S3 and Figs. S1--S5](http://www.jbc.org/cgi/content/full/RA117.001379/DC1).

The abbreviations used are: AMPKAMP-activated protein kinaseCDKcyclin-dependent kinasemTORmammalian target of rapamycinAICAR5-aminoimidazole-4-carboxamide 1-β-[d]{.smallcaps}-ribofuranosidePIpropidium iodideBrdUbromodeoxyuridinePPPpentose phosphate pathwayERKextracellular signal-regulated kinaseATPγSadenosine 5′-*O*-(thiotriphosphate)ASanalog-specificthioPthiophosphate2DG2-deoxyglucoseLKB1liver kinase B1DMEMDulbecco\'s modified Eagle\'s mediumGSTglutathione *S*-transferaseMBPmaltose-binding protein.

[^1]: Edited by Phyllis I. Hanson
